Patient characteristics according to treatment
| . | Chemotherapy+ allo-HSCT (n = 61) . | Chemotherapy+ auto-HSCT (n = 16) . | Chemotherapy without consolidation (n = 222) . |
|---|---|---|---|
| Age, median (range), y | 50 (18-70) | 63 (19-68) | 68 (18-87) |
| Disseminated with cutaneous involvement | 37 (60) | 12 (75) | 133 (60) |
| Disseminated noncutaneous | 12 (20) | 1 (6) | 20 (9) |
| Cutaneous isolated | 12 (20) | 3 (19) | 69 (31) |
| ALL-type | 33 (53) | 6 (38) | 57 (26) |
| AML-type | 16 (27) | 1 (6) | 36 (16) |
| NHL-type | 12 (20) | 9 (56) | 129 (58) |
| Response to treatment | |||
| CR | 57 (94) | 16 (100) | 153 (69) |
| PR | 2 (3) | 0 | 31 (14) |
| PD | 2 (3) | 0 | 38 (17) |
| Relapse | 16/60 (27) | 5/16 (31) | 131/168 (78) |
| . | Chemotherapy+ allo-HSCT (n = 61) . | Chemotherapy+ auto-HSCT (n = 16) . | Chemotherapy without consolidation (n = 222) . |
|---|---|---|---|
| Age, median (range), y | 50 (18-70) | 63 (19-68) | 68 (18-87) |
| Disseminated with cutaneous involvement | 37 (60) | 12 (75) | 133 (60) |
| Disseminated noncutaneous | 12 (20) | 1 (6) | 20 (9) |
| Cutaneous isolated | 12 (20) | 3 (19) | 69 (31) |
| ALL-type | 33 (53) | 6 (38) | 57 (26) |
| AML-type | 16 (27) | 1 (6) | 36 (16) |
| NHL-type | 12 (20) | 9 (56) | 129 (58) |
| Response to treatment | |||
| CR | 57 (94) | 16 (100) | 153 (69) |
| PR | 2 (3) | 0 | 31 (14) |
| PD | 2 (3) | 0 | 38 (17) |
| Relapse | 16/60 (27) | 5/16 (31) | 131/168 (78) |
Unless otherwise noted, data are n (%). Patients treated with new drugs (n = 6), radiotherapy (n = 27), or palliative approaches (n = 62) were excluded.